AlphaMind Brands Inc is entering the functional mushrooms market.
Exploring the companies and themes that make up this emerging and exciting new sector
MindMed Launches Project Lucy Focused On LSD Experiential Therapy For Anxiety Disorders
MindMed has high hopes for its new LSD-based anxiety therapy.
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Numinus adds to its management team.
MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Psychedelic Drug Therapy: Laying Out The Picture
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
Dr. Gabor Maté joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
MindMed Closes on Upsized Financing of $13.2m
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Champignon Appoints Dr. Bill Wilkerson to Board of Directors
Champignon Brands' new Director has extensive mental health credentials.
What A Trip! Psychedelics Stocks Flying High
Several psychedelics companies have generated impressive returns for investors in recent weeks.
Mota Ventures Talks Strategy: Mushrooms and CBD
Mota Ventures is in the process of acquiring psychedelics manufacturer, Verrian.
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
Numinus names a new Chief Medical Officer.
Numinus Takes Off On Initial Day Of Trading
Numinus Wellness is a new psychedelics stock that is up over 300% on its initial day of trading.